S100A8/A9: a Janus-faced molecule in cancer therapy and tumorgenesis.
Eur J Pharmacol
; 625(1-3): 73-83, 2009 Dec 25.
Article
en En
| MEDLINE
| ID: mdl-19835859
Correlations exist between the abundance of S100 proteins and disease pathologies. Indeed, this is evidenced by the heterodimeric S100 protein complex S100A8/A9 which has been shown to be involved in inflammatory and neoplastic disorders. However, S100A8/A9 appears as a Janus-faced molecule in this context. On the one hand, it is a powerful apoptotic agent produced by immune cells, making it a very fascinating tool in the battle against cancer. It spears the risk to induce auto-immune response and may serve as a lead compound for cancer-selective therapeutics. In contrast, S100A8/A9 expression in cancer cells has also been associated with tumor development, cancer invasion or metastasis. Clearly, there is a dichotomy and future investigations into the role of S100A8/A9 in cancer biology need to consider both sides of the same coin.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Calgranulina A
/
Calgranulina B
/
Neoplasias
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Eur J Pharmacol
Año:
2009
Tipo del documento:
Article
País de afiliación:
Canadá
Pais de publicación:
Países Bajos